Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition

Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence

(2018) Jie Dou et al.   Oncotarget

TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy

(2018) Lingyun Li et al.   Cell Metabolism

Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein in solid tumors

(2017) Wei-yi Gong et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40

(2017) Haijuan Yang et al.   NATURE

Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation

(2017) Jesus Cosin-Roger et al.   Nature Communications

mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells

(2016) Raju V. Pusapati et al.   CANCER CELL

Baicalin and baicalein inhibit transforming growth factor-β1-mediated epithelial-mesenchymal transition in human breast epithelial cells

(2015) Heesung Chung et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A novel effect of DMOG on cell metabolism: direct inhibition of mitochondrial function precedes HIF target gene expression

(2015) Alexander V. Zhdanov et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Metabolic Reprogramming of Immune Cells in Cancer Progression

(2015) Subhra K. Biswas   IMMUNITY

Colon cancer chemopreventive effects of baicalein, an active enteric microbiome metabolite from baicalin

(2015) CHONG-ZHI WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Anti-H1N1 virus, cytotoxic and Nrf2 activation activities of chemical constituents from Scutellaria baicalensis

(2015) Shuai Ji et al.   JOURNAL OF ETHNOPHARMACOLOGY

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

(2015) Go J. Yoshida   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The effects of baicalein and baicalin on mitochondrial function and dynamics: A review

(2015) Marcos Roberto de Oliveira et al.   PHARMACOLOGICAL RESEARCH

Vasohibin-1 suppresses colon cancer

(2015) Shuai Liu et al.   Oncotarget

Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism

(2015) Guo-Qing Chen et al.   Oncotarget

Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma

(2015) Nancy E. Thomas et al.   JAMA Oncology

Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase

(2014) Yue Ding et al.   ARCHIVES OF VIROLOGY

TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence

(2014) J. Ye et al.   EMBO Molecular Medicine

Baicalein induces autophagic cell death through AMPK/ULK1 activation and downregulation of mTORC1 complex components in human cancer cells

(2014) Pramod Aryal et al.   FEBS Journal

Nitric Oxide Synthase Inhibition with the Antipterin VAS203 Improves Outcome in Moderate and Severe Traumatic Brain Injury: A Placebo-Controlled Randomized Phase IIa Trial (NOSTRA)

(2014) John F. Stover et al.   JOURNAL OF NEUROTRAUMA

Potential Therapeutic Effects of Baicalein, Baicalin, and Wogonin in Ocular Disorders

(2014) Jing-Ru Xiao et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

MEK targeting in N-RAS mutated metastatic melanoma

(2014) Jaykumar Thumar et al.   Molecular Cancer

mTOR- and HIF-1 -mediated aerobic glycolysis as metabolic basis for trained immunity

(2014) S.-C. Cheng et al.   SCIENCE

Natural products: A continuing source of novel drug leads

(2013) Gordon M. Cragg et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Advances in therapy for melanoma brain metastases

(2013) Jaclyn C. Flanigan et al.   CLINICS IN DERMATOLOGY

Pretreatment of baicalin and wogonoside with glycoside hydrolase: A promising approach to enhance anticancer potential

(2013) CHUNHAO YU et al.   ONCOLOGY REPORTS

MYC, Metabolism, Cell Growth, and Tumorigenesis

(2013) C. V. Dang   Cold Spring Harbor Perspectives in Medicine

Human regulatory T cells induce T-lymphocyte senescence

(2012) J. Ye et al.   BLOOD

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

(2012) Patrick S. Ward et al.   CANCER CELL

SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor

(2012) Fred M. Kaplan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin

(2012) Yi Huang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

(2012) Kavitha Gowrishankar et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

(2012) Lawrence N Kwong et al.   NATURE MEDICINE

Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway

(2012) HONG-BO ZHANG et al.   Oncology Letters

Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells

(2011) Hiroki Takahashi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Carnosol: A promising anti-cancer and anti-inflammatory agent

(2011) Jeremy J. Johnson   CANCER LETTERS

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

(2011) Q. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Baicalein inhibits the migration and invasive properties of human hepatoma cells

(2011) Yung-Wei Chiu et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

(2010) F M Kaplan et al.   ONCOGENE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

Impact of Natural Products on Developing New Anti-Cancer Agents†

(2009) Gordon M. Cragg et al.   CHEMICAL REVIEWS